Medicinal Product Support in South Africa 
End-to-End Medicinal Product Regulatory Support in South Africa

Medicinal Product Support in South Africa - Overview

The medicinal products market in South Africa is evolving steadily, supported by the South African Health Products Regulatory Authority’s ongoing efforts to streamline review timelines through risk-based and reliance approaches, strengthening the SAHPRA approval process.

All medicinal products must obtain SAHPRA approval before they can be marketed or distributed for human or veterinary use. Despite improvements in efficiency, the authority’s specific requirements for medicinal product registration in South Africa, including initial registrations, post-approval variations, and lifecycle management (LCM), continue to require careful Regulatory planning, especially for new entrants navigating SAHPRA drug registration.

Freyr provides specialized Regulatory support South Africa pharmaceuticals, offering services such as development-stage guidance, gap analysis, and tailored remediation strategies aligned with local requirements. Support spans initial marketing authorizations, post-approval variations SAHPRA, and lifecycle management—helping companies achieve compliant and timely market access.

Medicinal Product Classification in South Africa

In South Africa, medicinal products are primarily classified based on a scheduling system governed by the South African Health Products Regulatory Authority under the Medicines and Related Substances Act, 1965.

1. Scheduling-Based Classification (Core System)

Medicines are classified into Schedules (Schedule 0–8) depending on their safety profile, potential for abuse, and level of medical supervision required:

• Schedule 0–2:
  • Low-risk medicines (e.g., many OTC products) – available with minimal or no prescription control
• Schedule 3–6:
  • Prescription-only medicines require increasing levels of medical supervision
• Schedule 7–8:
  • Highly controlled substances – strict regulation due to high abuse potential

This scheduling determines:

• Prescription and dispensing requirements
• Storage and record-keeping obligations
• Advertising restrictions

2. Registration Status Classification

Medicinal products are also categorized based on their Regulatory status within the SAHPRA drug registration framework:

• Registered Medicines: Fully evaluated and approved by SAHPRA
• Unregistered Medicines (Section 21 / Category A): Allowed on a case-by-case basis for specific patients under controlled access pathways

3. Broad Product-Type Grouping (Regulatory Context)

While scheduling is the primary classification system, medicines are also broadly grouped for Regulatory purposes into:

• Human medicinal products
• Veterinary medicinal products
• Complementary medicines (e.g., herbal or traditional products)

Medicinal Product Drug Registration & Approval in South Africa

In South Africa, all medicinal products must be approved by the South African Health Products Regulatory Authority before they can be marketed or distributed for human or veterinary use. This requirement is established under the Medicines and Related Substances Act, 1965 (Act 101 of 1965) and forms the basis of SAHPRA drug registration.

1. Application for Marketing Authorization (MAA)

Applicants are required to submit a complete dossier in CTD or eCTD format, aligned with SAHPRA guidelines and CTD eCTD submission South Africa requirements:

• Module 1: Regional administrative information
• Module 2: Overviews and summaries
• Module 3: Quality (CMC)
• Module 4: Non-clinical reports
• Module 5: Clinical reports

This structure is officially adopted by SAHPRA and harmonized with ICH standards.

2. Screening and Validation

• SAHPRA conducts an initial administrative screening to confirm completeness
• Incomplete applications are not accepted for full review until deficiencies are addressed

3. Scientific Evaluation

A full scientific assessment is conducted covering:

• Quality (CMC)
• Safety (non-clinical)
• Efficacy (clinical)

SAHPRA may issue queries (deficiency letters) during this phase, requiring applicant responses within defined timelines.

4. Review Pathways (Reliance Models)

SAHPRA has formally implemented facilitated Regulatory pathways, including:

• Full Review – complete independent assessment
• Abridged Review – partial reliance on prior approvals by recognized reference Regulatory authorities
• Verification Review – confirmation of prior approval with limited re-assessment

These pathways are part of SAHPRA’s reliance strategy, which is publicly documented and actively used to improve efficiency and address historical backlogs.

5. GMP Compliance

• Manufacturing sites must comply with the GMP compliance requirements in South Africa
• SAHPRA may rely on inspection reports or GMP certificates from recognized authorities or conduct its own inspections where required

6. Approval and Registration

• Upon successful evaluation, SAHPRA grants marketing authorization (registration)
• The product is assigned a registration number and a schedule (0–8 classification) in line with South African scheduling regulations

7. Timelines

Timelines are not fixed and depend on:

• Chosen review pathway
• Quality and completeness of the dossier
• Applicant responsiveness to queries

SAHPRA has made documented progress in reducing backlogs and improving review timelines, though variability still exists.

8. Post-Approval Obligation

• Pharmacovigilance (PV) requirements
• Post-approval variations (amendments)
• Product renewals and lifecycle management pharmaceutical South Africa

8. Access to Unregistered Medicines

• Under Section 21 of the Medicines Act, SAHPRA may authorize access to unregistered medicines on a named-patient basis under controlled conditions